NIO Inc. (NIO) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2280276/nio-inc-nio-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2280276
May 28, 2024 - In the closing of the recent trading day, NIO Inc. (NIO) stood at $4.90, denoting a +1.45% change from the preceding trading day.
0
AGNC Investment (AGNC) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2280278/agnc-investment-agnc-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2280278
May 28, 2024 - In the closing of the recent trading day, AGNC Investment (AGNC) stood at $9.59, denoting a -0.52% change from the preceding trading day.
0
Broadcom Inc. (AVGO) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2280279/broadcom-inc-avgo-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2280279
May 28, 2024 - Broadcom Inc. (AVGO) closed at $1,412.45 in the latest trading session, marking a +0.33% move from the prior day.
0
AstraZeneca, Daiichi Sankyo ADC misses key endpoint in phase 3 lung cancer trial
https://seekingalpha.com/news/4110802-astrazeneca-daiichi-sankyo-antibody-drug-comjugate-misses-key-endpoint-phase-3-lung-cancer-trial?source=feed_sector_healthcare
May 28, 2024 - AstraZeneca and Daiichi Sankyo's lung cancer antibody drug conjugate,, datopotamab deruxtecan, did not significantly improve overall survival in a phase 3 trial. Read more here.
0
Markets Wait for Key Economic Data
https://www.zacks.com/stock/news/2280106/markets-wait-for-key-economic-data?cid=CS-ZC-FT-economic_highlights-2280106
May 28, 2024 - Markets Wait for Key Economic Data.
0
Holiday-Shortened Week to Bring Key Data
https://www.zacks.com/stock/news/2280094/holiday-shortened-week-to-bring-key-data?cid=CS-ZC-FT-ahead_of_wall_street-2280094
May 28, 2024 - We've already got Case-Shiller home prices and words from the Minneapolis Fed President this morning.
0
Here's What Key Metrics Tell Us About CAE (CAE) Q4 Earnings
https://www.zacks.com/stock/news/2279970/here-s-what-key-metrics-tell-us-about-cae-cae-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2279970
May 28, 2024 - While the top- and bottom-line numbers for CAE (CAE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
Seeking Clues to CAE (CAE) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
https://www.zacks.com/stock/news/2279356/seeking-clues-to-cae-cae-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2279356
May 27, 2024 - Besides Wall Street's top -and-bottom-line estimates for CAE (CAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
0
What Analyst Projections for Key Metrics Reveal About Capri Holdings (CPRI) Q4 Earnings
https://www.zacks.com/stock/news/2279355/what-analyst-projections-for-key-metrics-reveal-about-capri-holdings-cpri-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2279355
May 27, 2024 - Get a deeper insight into the potential performance of Capri Holdings (CPRI) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
0
This Ultra-High-Yielding Dividend Stock Solved a Key Pain Point
https://www.fool.com/investing/2024/05/25/this-ultra-high-yielding-dividend-stock-solved-a-k/?source=iedfolrf0000001
May 25, 2024 - Medical Properties Trust secured a deal to refinance debt that's maturing over the next year.
0